Medpace (NASDAQ:MEDP) CEO August Troendle Sells 458 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 458 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $600.39, for a total value of $274,978.62. Following the sale, the chief executive officer directly owned 603,978 shares of the company’s stock, valued at $362,622,351.42. This trade represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $578.50 on Friday. The stock has a market cap of $16.15 billion, a price-to-earnings ratio of 33.91, a PEG ratio of 2.60 and a beta of 1.15. The business has a 50 day simple moving average of $536.23 and a 200 day simple moving average of $492.35. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Institutional Trading of Medpace

Hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its holdings in shares of Medpace by 22.1% during the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares in the last quarter. Cerity Partners LLC raised its stake in shares of Medpace by 41.0% in the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after purchasing an additional 23,530 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Medpace by 24,930.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after purchasing an additional 100,968 shares during the period. Mitchell Capital Management Co. bought a new position in Medpace in the fourth quarter worth $3,383,000. Finally, M&T Bank Corp lifted its position in Medpace by 1,596.0% in the fourth quarter. M&T Bank Corp now owns 14,128 shares of the company’s stock worth $7,935,000 after purchasing an additional 13,295 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Mizuho boosted their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and upped their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Royal Bank Of Canada increased their price objective on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Finally, Robert W. Baird raised their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.